Cargando…

Pharmacodynamic Biomarkers for Quantifying the Mycobacterial Effect of High Doses of Rifampin in Patients with Rifampin-susceptible Pulmonary Tuberculosis

BACKGROUND: Suboptimal drug exposure in patients with drug-susceptible tuberculosis (DS-TB) can drive treatment failure. Pharmacodynamics (PD) biomarkers such as the plasma TB drug-activity (TDA) assay may guide dose finding studies and predict microbiological outcomes differently than conventional...

Descripción completa

Detalles Bibliográficos
Autores principales:	Said, Bibie N, Heysell, Scott K, Yimer, Getnet, Aarnoutse, Rob E., Kibiki, Gibson S, Mpagama, Stellah, Mbelele, Peter M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7612567/ https://www.ncbi.nlm.nih.gov/pubmed/34916467 http://dx.doi.org/10.4103/ijmy.ijmy_178_21

Ejemplares similares

Pharmacokinetic-Pharmacodynamic Determinants of Clinical Outcomes for Rifampin-Resistant Tuberculosis: A Multisite Prospective Cohort Study
por: Heysell, Scott K, et al.
Publicado: (2022)

Discordance in Mycobacterium tuberculosis Rifampin Susceptibility
por: Kalokhe, Ameeta S., et al.
Publicado: (2012)

Rifampin Pharmacokinetics/Pharmacodynamics in the Hollow-Fiber Model of Mycobacterium kansasii Infection
por: Srivastava, Shashikant, et al.
Publicado: (2022)

Gridlock from diagnosis to treatment of multidrug-resistant tuberculosis in Tanzania: low accessibility of molecular diagnostic services and lack of healthcare worker empowerment in 28 districts of 5 high burden TB regions with mixed methods evaluation
por: Mpagama, Stellah G., et al.
Publicado: (2019)

Gridlock from diagnosis to treatment of multidrug resistant tuberculosis (MDR-TB) in Tanzania: patients’ perspectives from a focus group discussion
por: Mpagama, Stellah G., et al.
Publicado: (2020)

Application of quantitative second-line drug susceptibility testing at a multidrug-resistant tuberculosis hospital in Tanzania
por: Mpagama, Stellah G, et al.
Publicado: (2013)

Etymologia: Rifampin
por: Henry, Ronnie
Publicado: (2018)

Characterization of rifampin-resistant Staphylococcus aureus nasal carriage in patients receiving rifampin-containing regimens for tuberculosis
por: Huang, Yu-Tsung, et al.
Publicado: (2018)

Mycobacterium tuberculosis and Rifampin Resistance, United Kingdom
por: Sam, I-Ching, et al.
Publicado: (2006)

Early Therapeutic Drug Monitoring for Isoniazid and Rifampin among Diabetics with Newly Diagnosed Tuberculosis in Virginia, USA
por: Heysell, Scott K., et al.
Publicado: (2013)

Emergence and selection of isoniazid and rifampin resistance in tuberculosis granulomas
por: Pienaar, Elsje, et al.
Publicado: (2018)

1323. Substantial Doses of Daptomycin and Rifampin Eradicate S. epidermidis Biofilm in an In Vitro Pharmacodynamic (IVPD) Model
por: Piehl, Emily C, et al.
Publicado: (2020)

Rifampin-resistant Meningococcal Disease
por: Rainbow, Jean, et al.
Publicado: (2005)

Rifampin-resistant Neisseria meningitidis
por: Taha, Muhamed-Kheir, et al.
Publicado: (2006)

An Overlooked Cause of Rifampin Resistance
por: Agha, Yasmine Hussein, et al.
Publicado: (2020)

Rifampin-Associated Renal Failure
por: Miller, Kathleen, et al.
Publicado: (2023)

Underestimated pyrazinamide resistance may compromise outcomes of pyrazinamide containing regimens for treatment of drug susceptible and multi-drug-resistant tuberculosis in Tanzania
por: Juma, Saumu Pazia, et al.
Publicado: (2019)

Highly Synergistic Effects of Melittin With Vancomycin and Rifampin Against Vancomycin and Rifampin Resistant Staphylococcus epidermidis
por: Mirzaei, Rasoul, et al.
Publicado: (2022)

Improved performance of Xpert MTB/RIF assay on sputum sediment samples obtained from presumptive pulmonary tuberculosis cases at Kibong’oto infectious diseases hospital in Tanzania
por: Mbelele, Peter M., et al.
Publicado: (2017)

The molecular basis of resistance to isoniazid, rifampin, and pyrazinamide in Mycobacterium tuberculosis
por: Somoskovi, Akos, et al.
Publicado: (2001)

Mycobacterium tuberculosis Beijing Genotype Resistance to Transient Rifampin Exposure
por: den Hertog, Alice L., et al.
Publicado: (2014)

Oxycodone Resistance Due to Rifampin Use in an Osteosarcoma Patient with Tuberculosis
por: Sakamoto, Akio, et al.
Publicado: (2017)

Influence of Single Nucleotide Polymorphisms on Rifampin Pharmacokinetics in Tuberculosis Patients
por: Thomas, Levin, et al.
Publicado: (2020)

rpoB Mutations and Effects on Rifampin Resistance in Mycobacterium tuberculosis
por: Li, Ma-chao, et al.
Publicado: (2021)

Evaluation of the Antibody in Lymphocyte Supernatant Assay to Detect Active Tuberculosis
por: Sariko, Margaretha, et al.
Publicado: (2017)

Delayed Rifampin Administration in the Antibiotic Treatment of Periprosthetic Joint Infections Significantly Reduces the Emergence of Rifampin Resistance
por: Darwich, Ali, et al.
Publicado: (2021)

Need to confirm isoniazid susceptibility in Xpert MTB/RIF rifampin susceptible cases
por: Vadwai, Viral, et al.
Publicado: (2012)

Deranged Haemostasis: Rifampin-Induced Coagulopathy
por: Tiperneni, Raghu, et al.
Publicado: (2022)

Protocol for a feasibility randomized controlled trial to evaluate the efficacy, safety and tolerability of N-acetylcysteine in reducing adverse drug reactions among adults treated for multidrug-resistant tuberculosis in Tanzania
por: Mpagama, Stellah G., et al.
Publicado: (2023)

Radical scavenging of poly(methyl methacrylate) bone cement by rifampin and clinically relevant properties of the rifampin-loaded cement
por: Funk, G. A., et al.
Publicado: (2019)

Cutaneous leukocytoclastic vasculitis due to anti-tuberculosis medications, rifampin and pyrazinamide
por: Kim, Joo-Hee, et al.
Publicado: (2010)

Healthcare Provider Discrimination toward Pregnant Women with Rifampin-Resistant Tuberculosis
por: Loveday, Marian, et al.
Publicado: (2019)

Genotyping of rifampin-resistant Mycobacterium tuberculosis isolates from western Turkey
por: Cavusoglu, Cengiz, et al.
Publicado: (2004)

Molecular fingerprinting reveals familial transmission of rifampin-resistant tuberculosis in Kuwait
por: Mokaddas, Eiman, et al.
Publicado: (2005)

Genetic Determinants of the Pharmacokinetic Variability of Rifampin in Malawian Adults with Pulmonary Tuberculosis
por: Sloan, Derek J., et al.
Publicado: (2017)

Abacavir Exposure in Children Cotreated for Tuberculosis with Rifampin and Superboosted Lopinavir-Ritonavir
por: Rabie, Helena, et al.
Publicado: (2020)

Improving Quality of Patient Data for Treatment of Multidrug- or Rifampin-Resistant Tuberculosis
por: Campbell, Jonathon R., et al.
Publicado: (2020)

Decentralized Care for Rifampin-Resistant Tuberculosis, Western Cape, South Africa
por: Leavitt, Sarah V., et al.
Publicado: (2021)

Tuberculosis Variant with Rifampin Resistance Undetectable by Xpert MTB/RIF, Botswana
por: Modongo, Chawangwa, et al.
Publicado: (2023)

Ability of the MeltPro MTB/PZA Assay to Detect Susceptibility to Pyrazinamide in Rifampin-Resistant Tuberculosis Patients
por: Li, Rong, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_5sjnblo08vk91bmmrs7rbb8c7p